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Understanding the Ureter:
Challenges and Opportunities
Alyssa Park, MD, and Ramakrishna Venkatesh, MD

Abstract

The ureter is possibly the least studied and most poorly understood organ of the urinary tract. The pathophysiologic basis underlying the use of a-blockers to improve ureteral stone passage or to treat ureteral stent
symptoms is poorly understood. This, in part, may explain why clinical studies of medical expulsive therapy for
ureteral stone passage are fraught with conflicting data. Methods to study human ureter in vivo are few and
challenging. The findings of many of the ureteral studies are from observational in vitro studies and were
evaluated in other animal species that may not be applicable in human beings. There are few mechanistic
studies evaluating the underlying molecular pathophysiologic mechanisms of human ureter. This is critical to
our understanding and treatment of stent symptoms, including the development of a patient friendly ureteral
stent and for the pharmacologic modulation of ureteral activity. The following is an overview of some of the
observational and mechanistic ureteral studies evaluating the pharmacologic and stent effects, including potential areas for further research.
Introduction

U

Ureteral Stent Studies

rologists have been using ureteral stents for more
than four decades.1 However, the exact mechanisms
of ureteral stent pain, dilation of ureter with stenting,
and treatment of ureteral stent symptoms are still elusive.
Over the last decade, there has been wide use of alphablocker for ureteral stone passage and stent symptoms.
There are many single-center studies confirming the
benefit of alpha-blocker for stone passage, but a more recent well-designed, large, randomized prospective study
showed no benefit of alpha-blocker in decreasing the
treatment intervention rate compared with a placebo
group.2,3 The earlier examples bring to question our understanding of the ureteral pathophysiologic mechanisms
related to the use of ureteral stent and pharmacotherapy of
ureteral stone passage.
The study of ureteral dynamics and smooth-muscle pharmacology has drawn significant conflicting findings, possibly
because of the many differences in experimental techniques,
animal models, and lack of sensitive instrumentation. Many
authors have reported in vitro and in vivo ureteral studies
related to ureteral instrumentation such as stenting and the
effects of pharmacologic agents in many animal species that
may not be transferable to human clinical application. The
following overview of previous ureteral studies highlights
some of the challenges in studying the ureter and potential
opportunities for future research.

Animal studies

Ureteral stents help patients with stone colic by relieving
renal obstruction. However, ureteral stents can cause partial
obstruction to the upper urinary tract with rise in intrapelvic
pressure that may contribute to the ureteral dilation. However,
the intrapelvic pressure is known to decrease to normal levels
in 3 weeks and hence the rise in intrapelvic pressure cannot
fully explain ureteral dilation.4 Normal peristalsis is affected
by the ureteral stent as demonstrated by in vivo animal ureteral
studies. In a swine model, normal peristalsis was absent after
24 hours following ureteral stenting and peristalsis returned on
day 5.5 In another porcine in vivo study, the peristaltic activity
in response to stent placement increased immediately but decreased after 4–5 hours. Peristalsis was markedly reduced or
abolished completely after 1 week.6 If stone pain is partly from
ureteral spasm, ureteral aperistalsis induced by the presence of
a stent may alleviate pain of ureteral colic.
The effects of calcitonin gene-related peptide (CGRP) on the
ureter in another animal study provide another possible mechanism of action of ureteral stent pain. The CGRP peptide is a
smooth-muscle relaxant and inhibits peristalsis.5 This could
cause both dilation of the ureter and reduction of peristalsis. This
peptide is released from unmyelinated sensory nerve endings in
the ureter by pain stimulation such as a ureteral stent. It seems
possible that both the initial increased upper tract pressure and
CGRP may play a role in ureteral dilation/paralysis with
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stenting. In an in vivo stented porcine ureter, we studied the
effects of an alpha-blocker on the ureteral peristalsis and intrapelvic pressure.7 Alpha-blocker resulted in no significant effect on renal pelvic pressure, but a significant decrease in the
number of ureteral peristalsis. Further investigation of the effects
of alpha-blocker on ureteral dynamics is required to better understand its effects on stent-related symptoms.
Human studies

The in vivo ureteral studies related to ureteral instrumentation
or stenting in humans are sparse. Miller and coworkers described
the use of a ureteral catheter with pressure transducers that could
measure ureteral peristaltic frequency and ureteral intraluminal
pressure in an ambulatory situation.5 The authors used a single
4F ureteral catheter and reported their findings in six patients.
Five subjects showed peristalsis on catheter insertion. Eighteen
hours following ureteral catheter insertion, two had no peristalsis. One of these subjects had previously had a Double-J stent
in situ for 10 weeks and the other patient had diclofenac for
postoperative analgesia. One patient had diclofenac suppository
before surgery and was found to have no peristalsis during the
recording for over 24 hours. Excluding these three patients, the
average baseline peristaltic rate was 2/min (range 2–4/min).
Thus, in the earlier human study, the recently instrumented
ureters displayed a variable peristaltic and pressure response that
appeared to be related to previous physical or pharmacologic
effects. The earlier study also showed in vivo evidence that diclofenac abolishes peristalsis in a human ureter.
In many patients, ureteral stents cause significant bothersome
urinary symptoms (78%), stent pain (80%), sexual dysfunction
(31%), and decreased work capacity (57%). However, there are
few effective treatments for stent symptoms. A meta-analysis of
several trials showed that alpha-blockers improve stent-related
symptoms, including quality of life in patients with stents and
recommend their use in clinical practice.8 In an interesting study,
Gupta et al. evaluated in a randomized controlled study the effects of ipsilateral periureteral injection of botulinum toxin type
A at a concentration of 10 U/mL at three sites around the ureteral
orifice after ureteral stenting. They administered Ureteral Stent
Symptoms Questionnarie (USSQ) 7 days after stent insertion and
reported a significant decrease in postoperative pain and narcotic
use, but no significant impact on any USSQ scores.9
Novel stents

Landman and his coworkers recently reported on custommade ureteral stents where they printed ureteral stents using a
three-dimensional printer. They evaluated the above in porcine and cadaver models.10 This is a fascinating area where
surgical devices can potentially be printed in the operating
room with implications on cost savings and the potential to
create a specific sized and shaped device for each patient.
Common stent complications included encrustation, infection, pain, and discomfort. In recent years, progress has
been made in the development of drug-eluting stents to improve the biocompatibility. Cadieux and colleagues reported
on the use of triclosan-loaded ureteral stents to reduce stentassociated bacterial attachment, biofilm formation, and encrustation to potentially reduce infection. They performed a
randomized study comparing the triclosan eluting stent with a
noneluting stent.11 No significant differences were observed
for culture, biofilm, and encrustation between the two groups.
However, the triclosan eluting stent led to significant reduc-
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tions in several common ureteral stent-related symptoms,
supporting its use in this patient population.
Effects of Medications on Ureteral Activity

a1-Adrenoceptors (both 1A and 1D) have been detected both
in animal and human ureters. Similar to muscarinic receptors,
activation of a1-adrenoceptors can activate the phospholipase
C/inositol trisphosphate-diacylglycerol pathway and may
cause ureteral contraction. The ureter has efferent and afferent
innervation from cholinergic, adrenergic, nonadrenergic, and
noncholinergic components. Innervation of the lower ureter is
shown to be denser than the upper ureter in humans.
Animal studies

Nakada et al. evaluated doxazosin effects on the ureteral
activity. This mechanistic in vitro porcine ureteral strips organ
bath study showed that doxazosin reduces spontaneous and
alpha(1)-agonist-induced ureteral contractility. No differential
expression of alpha(1)-receptor subtypes was identified in the
obstructed vs normal ureters. They hypothesized that alphareceptor blockade might relax the ureter and induce stone
passage by epinephrine activation of beta-receptors.12
Pick et al. studied urothelial permeability. By pretreating
the intraluminal surface of the ureter with chitosan, which
increases urothelial permeability, nifedipine blocks ureteral
peristalsis at low concentrations.13 They found chitosan
changes ureteral urothelial permeability without barrier disruption and had no observed effect on ureteral contraction.
Human studies

Davenport et al. used a ureteral pressure transducer catheter
in vivo to evaluate the ureteral pressure response to tamsulosin,
diclofenac, and nifedipine in 13 patients.14 Five French catheter
was inserted into the contralateral ureter following ureteroscopy for stone disease. Patients were admitted to the hospital.
Peristaltic frequency and ureteral pressure measurements were
recorded at 24 hours. Each patient was randomly allocated to
receive oral diclofenac, nifedipine, or tamsulosin. Measurements were taken following drug administration. Before drug
administration, the mean number of contractions recorded was
0–4.1/min and the peak contraction pressure ranged from 11 to
35 mm Hg. Ureteral peristalsis persisted in all patients despite
these drugs. Diclofenac and nifedipine produced inconsistent
ureteral pressure responses but had little effect on contraction
frequency. Tamsulosin significantly reduced ureteral pressure
but had no effect on peristaltic frequency.
Adrenergic stimuli in the obstructed ureter produce increased contractility, which is blocked by adrenergic receptor
blockers as first shown by Peters and Eckstein in canine ureters.15 They showed that use of a nonspecific alpha adrenergic
blocker increased urinary flow while decreases the frequency of
ureteral contractions in partially obstructed ureters. Specific
alpha-1 blockade has received increased interest recently.
Several randomized studies show shorter stone passage time
and increased stone expulsion with alpha-blockers (tamsulosin)
compared with placebo or nifedipine.16 In these studies, distal
ureteral stones ranged in size from 4 to 6.7 mm and the stone
expulsion rate with alpha-blockade was 97%–100% compared
with 64%–70% in the placebo groups. All patients in these
studies were given steroids and antibiotics while taking the
study medications. With calcium channel blockers, the stone
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passage rate was 97% in patients given tamsulosin vs 77% for
those given nifedipine. Results to date seem to favor the use of
alpha-blockade over calcium channel blockers. Calcium
blocking action on cells has been proposed as a way to decrease
ureteral contractions and subsequently decrease the pain and
discomfort associated with ureteral stones. Nifedipine and verapamil decrease fast phasic contractions while leaving slow
phasic contractions unaffected, suggesting preservation of
peristalsis with decreased spasms. Relaxation of the ureter with
calcium channel blockade might also facilitate stone passage.
However, the exact ureteral dynamics related to this is not
known. Calcium channel blockers have been evaluated to see
their effect on pain from a ureteral stone. Caravati et al. compared nifedipine vs placebo in 30 patients.17 As measured on a
visual analog scale, no significant difference in pain was noted.
There is a growing body of literature demonstrating that calcium channel blockers may help with stone passage without
significantly altering pain. A large randomized trial comparing
placebo, tamsulosin, and nifedipine showed that tamsulosin
400 mg and nifedipine 30 mg are not effective at decreasing the
need for further treatment to achieve stone clearance in 4 weeks
for patients with expectantly managed ureteral colic. This shows
that we do not fully understand the pathophysiology of the effects
of drugs on the ureter. Randomized studies have demonstrated
similar efficacy between selective (tamsulosin) and nonselective
(terazosin and doxazosin) medications. Holdgate and Oh found
no significant differences in initial or later opioid use when randomizing patients to anticholinergic therapy.18 The addition of
anticholinergics did not seem to alter the pain level or facilitate
stone passage in patients with ureteral stones in this study.
Conclusions

There is a need for better characterization of ureteral receptors and other neurogenic factors and also the understanding of cellular mechanisms underlying neurogenic and
myogenic ureteral contractions. Also, the quest for better tools
to study the human ureteral activity in vivo continues. Ureter is
primarily a muscular organ transporting urine from the kidneys
to bladder, but pharmacomodulation of its smooth muscle
activity directly and indirectly through the autonomic and
other modulators can be clinically useful to facilitate ureteral
stone passage, ureteral instrumentation, such as ureteroscopy,
and possibly to minimize stent symptoms. Basic science
mechanistic studies understanding the molecular mechanisms
of ureteral activity along with observational studies are essential for the development of optimal stents and for the sound
use of pharmacologic agents to facilitate urinary stone passage.
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Abbreviation Used
CGRP ¼ calcitonin gene-related peptide

